About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
WASHINGTON, D.C. (March 15, 2022) – Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Megan Van Etten issued the following statement after news reports of developments concerning a proposed WTO TRIPS waiver on intellectual property for COVID-19 vaccines:
“The fact remains that efforts to waive intellectual property commitments are unnecessary and harmful to our collective work to end the pandemic. Strong intellectual property protections, voluntary technology transfers and partnerships are on target to facilitate the production of more than 20 billion doses in 2022 – more than enough to vaccinate the world – without confiscating intellectual property. Global leaders should now focus on the real challenges of distributing and administering vaccines to people around the world.”
Press Release
Intellectual Property
PhRMA Statement on WTO TRIPS Waiver Negotiations
PhRMA Statement on WTO TRIPS Waiver Negotiations image